Navigation Links
Simcere Pharmaceutical Group Appoints Dr. Peng Wang as Chief Scientific Officer
Date:5/19/2009

NANJING, China, May 19 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in China, announced today the appointment of Dr. Peng Wang as Chief Scientific Officer.

Dr. Wang will lead the company's R&D team in developing new products and innovative research projects. He will also participate in the strategic planning of the R&D department and manage domestic and international research collaborations.

Dr. Wang has two decades of experience in pharmaceutical R&D, most recently serving as Vice President of Discovery Biology at WuXi PharmaTech. Previously, Dr. Wang was a Research Fellow at Schering-Plough Research Institute where he worked for eighteen years with increasing responsibilities. Dr. Wang received his Ph.D. in Biochemistry from the University of Tokyo in 1990.

"As a recognized biopharmaceutical expert, Dr. Wang is well positioned to contribute to Simcere's strategic development in this area," commented Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group, "Simcere is committed to investing in research and development to support our long term growth, and we are delighted that Dr. Wang has agreed to join us."

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday, November 5, 2007
2. Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Promotions
3. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
4. Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
5. Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York
6. Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008
7. Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources
8. Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008
9. Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase
10. Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008
11. Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... Ca (PRWEB) , ... August 16, 2017 , ... ... by changing into a different cell type. Many treatments for specific cancers, such ... prominent example of targeted treatment is androgen deprivation therapy for advanced prostate cancer. ...
(Date:8/16/2017)... , Aug. 16, 2017  This year,s edition of the Inc. ... in life sciences workforce solutions, has made the list for the third ... recognizes the nation,s fastest-growing private companies based on a set of quantitative ... which includes the fastest-growing companies in the Bay State ... Inc. 5000 ...
(Date:8/15/2017)... ... August 15, 2017 , ... Nanomedical ... and biotherapeutics development, announces the launch of the new NHS Agile biosensor ... kinetic binding data for a wide range of molecules, including small and large ...
(Date:8/15/2017)... ... August 15, 2017 , ... The Conference Forum and The ... through a series of upcoming panels and events. The partnership culminates with the ... Hotel in New York City. , “With our experience in producing the Immuno-Oncology 360° ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
Breaking Biology News(10 mins):